SUVEN

leading CDMO (Contract Development and Manufacturing Organization) serving global pharmaceutical innovators. The company benefits from long-term customer relationships, strong capabilities in complex chemistry, and increasing outsourcing by global pharma companies. Following its merger with Cohance Lifesciences, Suven has expanded its scale and service offerings. The company maintains healthy margins, a strong balance sheet, and robust cash generation. Growth is supported by a strong project pipeline, rising demand for outsourced drug development, and increasing presence in regulated markets.